Alector (ALEC) Net Income towards Common Stockholders (2018 - 2026)

Alector's (ALEC) quarterly Net Income towards Common Stockholders came in at -$22.9 million in Q1 2026, up 43.34% year-on-year from -$16.0 million in Q1 2025, and up 38.19% on a QoQ basis from -$37.1 million in Q4 2025.

Alector (ALEC) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends

Alector (ALEC) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$22.9 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 43.34% year-over-year to -$22.9 million in Q1 2026; TTM through Mar 2026 was -$125.2 million, a 1.44% decrease from a year earlier, with the FY2025 full-year figure at -$142.8 million, down 19.92% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$22.9 million, up from -$37.1 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for ALEC reached as high as $9.9 million in Q2 2022 and fell as low as -$52.4 million in Q4 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$31.9 million across 5 years, with a median of -$37.1 million in 2025.
  • Across the five-year window, Net Income towards Common Stockholders jumped 117.92% in 2022 and sank 2912.8% in 2024, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$52.4 million in 2022, then jumped by 31.73% to -$35.8 million in 2023, then soared by 94.21% to -$2.1 million in 2024, then tumbled by 1688.77% to -$37.1 million in 2025, then soared by 38.19% to -$22.9 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$22.9 million in Q1 2026, -$37.1 million in Q4 2025, and -$34.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 Alector 166.99 Mn -39.52 Mn - -22.93 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -22.93 Mn
Dec 31, 2025 -37.10 Mn
Sep 30, 2025 -34.67 Mn
Jun 30, 2025 -30.52 Mn
Mar 31, 2025 -40.47 Mn
Dec 31, 2024 -2.07 Mn
Sep 30, 2024 -42.22 Mn
Jun 30, 2024 -38.68 Mn
Mar 31, 2024 -36.08 Mn
Dec 31, 2023 -35.79 Mn
Sep 30, 2023 -44.48 Mn
Jun 30, 2023 1.38 Mn
Mar 31, 2023 -45.86 Mn
Dec 31, 2022 -52.43 Mn
Sep 30, 2022 -46.15 Mn
Jun 30, 2022 9.88 Mn
Mar 31, 2022 -44.62 Mn
Dec 31, 2021 -47.98 Mn
Sep 30, 2021 126.60 Mn
Jun 30, 2021 -55.15 Mn